NPPB and pulmonary arterial hypertension: An ongoing phase 2, single-center, randomized placebo-controlled trial in adults with PAH including patients with PAH-CHD is evaluating the effects of famotidine in improving 6MWD, NYHA functional class, and decreasing BNP levels [76].